Videos and Events

Dolutegravir Based Regimens

Congress Data

The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1
GEMINI-1 and GEMINI-2 Studies
Michael Aboud, VP, Global Medical Lead, Dolutegravir

DTG/3TC: Real-World Evidence
An Update from CROI 2020
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

DTG: Metabolic Data Update
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator

TANGO Study: Metabolic Substudy
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

DTG/3TC: Barrier to Resistance
Jan van Lunzen, Head of Translational Medical Research

Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs

GEMINI 144 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

TANGO 96 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

GEMINI 48 Week: Adherence Analysis
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

STAT 24 Week: Feasibility, Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Clinical Trials Data

The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1
GEMINI-1 and GEMINI-2 Studies
Michael Aboud, VP, Global Medical Lead, Dolutegravir

Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator

TANGO Study: Metabolic Substudy
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting
Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs

GEMINI 144 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

TANGO 96 Week: Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

GEMINI 48 Week: Adherence Analysis
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

STAT 24 Week: Feasibility, Efficacy and Safety
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Dosing

Tivicay PD: An Option for Children Living with HIV
Ana M. Puga, MD, Regional Medical Director
Pharmacokinetics

Tivicay PD: An Option for Children Living with HIV
Ana M. Puga, MD, Regional Medical Director
Safety

Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs

DTG: Metabolic Data Update
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

TANGO Study: Metabolic Substudy
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Antiretroviral Therapy and Weight Gain
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
Virology/Resistance

Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study
Mark Underwood, Clinical Virologist and Development Investigator

DTG/3TC: Barrier to Resistance
Jan van Lunzen, Head of Translational Medical Research
Real World Evidence

DTG/3TC: Real-World Evidence
An Update from CROI 2020
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

Yes